Lupin Receives Approval for Oral Contraceptive Daysee Tablets in US Market
Lupin has received a final nod from US FDA for sale of Daysee pill in the U. S. market. The approval was given to Lupin's subsidiary Lupin Pharmaceuticals Inc for a contraceptive pill. Lupin has already begun shipping Daysee pills, which is a generic version of Seasonique tablets of Teva Pharmaceuticals.
The Daysee pills are for contraception in women, available for a long-term cycle. The pack consists of 84 light blue tablets and seven mustard colored tablets for 13 weeks.
The blue tablets comprise 0.15mg of Levonorgestrel and 0.03mg of Ethinyl estradiol, and mustard tablets comprise 0.01mg of Ethinyl estradio.
According to IMS MAT De Eg 2012, the total sales for both branded and generic products have soared to US$ 161 million. Lupin was quoting at Rs 665.80 at 09:30 hrs, which was Rs6.15 up. Also it has touched a 52-week high mark of Rs 668.70.
The share closed up 2.29 percent or Rs 14.75 at Rs 659.65 in the previous trading season. It was trading with the volumes of 9,113 shares. According to experts, the estimate of the latest book value of the company is Rs 83.45 per share and the current price-to-book value of the company was Rs 7.97.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids